Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Krzystof Simon"'
Effect of Opaganib on Supplemental Oxygen and Mortality in Patients with Severe SARS-CoV-2 Pneumonia
Autor:
Fernando Carvalho Neuenschwander, Ofra Barnett-Griness, Stefania Piconi, Yasmin Maor, Eduardo Sprinz, Nimer Assy, Oleg Khmelnitskiy, Nikita Lomakin, Boris Mikhailovich Goloshchekin, Ewelina Nahorecka, Adilson Joaquim Westheimer Calvacante, Anastasia Ivanova, Sergey Vladimirovich Zhuravel, Galina Yurevna Trufanova, Stefano Bonora, Amer Saffoury, Ami Mayo, Yury Shvarts, Giuliano Rizzardini, Rogerio Sobroza de Mello, Janaina Pilau, Alexey Klinov, Benjamin Valente-Acosta, Oleg Olegovich Burlaka, Natalia Bakhtina, Maskit Bar-Meir, Ivan Nikolaevich Shishimorov, Jose Oñate-Gutierrez, Cristian Ivan Garcia Rincon, Tatiana Ivanovna Martynenko, Ludhmila Abrahão Hajjar, Ana Carolina Nazare de Mendonca Procopio, Krzystof Simon, Walter Gabriel Chaves Santiago, Adam Fronczak, Conrado Roberto Hoffmann Filho, Osama Hussein, Vladimir Aleksandrovich Martynov, Guido Chichino, Piotr Blewaska, Jacek Wroblewski, Sergio Saul Irizar Santana, Andres Felipe Ocampo Agudelo, Adam Barczyk, Rachael L. Gerlach, Eppie Campbell, Aida Bibliowicz, Reza Fathi, Patricia Anderson, Gilead Raday, Michal Klein, Clara Fehrmann, Gina Eagle, Vered Katz Ben-Yair, Mark L. Levitt
RationaleThere are few treatment options for severe COVID-19 pneumonia. Opaganib is an oral treatment under investigation.ObjectiveEvaluate opaganib treatment in hospitalized patients with severe COVID-19 pneumonia.MethodsA randomized, placebo-contro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ac5a8655eb260c38557cc88d09eaf63c
https://doi.org/10.1101/2022.06.12.22276088
https://doi.org/10.1101/2022.06.12.22276088
